Kisqali vs Tagrisso
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Kisqali | US Tagrisso | |
|---|---|---|
| Generic name | ribociclib | osimertinib |
| Drug class | CDK4/6 Inhibitor | EGFR Tyrosine Kinase Inhibitor |
| Treats | HR-positive, HER2-negative breast cancer | EGFR-positive non-small cell lung cancer |
| Category | Oncology | Oncology |
| Manufacturer | Novartis | AstraZeneca |
| Year approved | 2017 | 2015 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $80M | — |
| Common side effects | Low white blood cells, Nausea, Fatigue, Heart rhythm changes (QT) | Diarrhea, Rash, Dry skin, Lung inflammation |
Frequently asked questions
Is Kisqali or Tagrisso better?
Neither is universally "better." Kisqali (ribociclib) and Tagrisso (osimertinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Kisqali and Tagrisso?
Kisqali is a CDK4/6 Inhibitor made by Novartis, while Tagrisso is a EGFR Tyrosine Kinase Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Kisqali has the larger estimated TV advertising budget of the two.